The Lancelot technology delivers enhanced hemodynamics through the integration of precision laser cutting and after ...

The FDA approved the Trilogy Transcatheter Heart Valve System for the treatment of symptomatic severe aortic regurgitation, device maker JenaValve Technology announced. This approval makes Trilogy the ...

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green light to treat severe backflow through the aortic valve. | JenaValve has ...

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.

WASHINGTON, DC—New data from the PARTNER 3 low-risk trial of patients with symptomatic, severe aortic stenosis show that TAVI ...

A new minimally invasive procedure replaces a damaged heart valve through a small neck incision, potentially allowing patients to recover faster than with traditional open-heart surgery.

Imagine your heart not functioning properly and you not knowing for years! That’s the reality of people with aortic valve disease. Symptoms include chest pain, dizziness, fatigue, and irregular ...

TAVR is a breakthrough, minimally invasive procedure used to treat severe aortic stenosis, a condition where the aortic valve narrows, hindering blood flow ...

When your aortic heart valve stops working, it puts you at risk for heart failure and stroke. Standard surgery involves big chest incisions, which can have painful recoveries. But Cleveland Clinic has ...

TAVR, a minimally invasive alternative to open‑heart surgery for severe aortic stenosis, has become the global standard for elderly and high‑risk patients.

S3V Vascular Technologies Limited announces its indigenous Balloon-Expandable TAVR system will enter preclinical studies, aiming to make cardiac care affordable across India.